BioSpace News Archive

Brooklyn ImmunoTherapeutics, Inc., a biopharmaceutical company focused on exploring the role that gene editing/cell and cytokine therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, announced financial results for the quarter ended June 30, 2021.

Oncotelic Therapeutics, Inc. and COVID-19 and Golden Mountain Partners, ( “ GMP ” ) announced that they are forming a joint venture ( “JV” ) to advance clinical development of Oncotelic’s pharmaceutical pipeline and build out of manufacturing facilities for the commercial launch of Oncotelic’s drug candidates.

TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced three upcoming poster presentations on its OviTex Reinforced Tissue Matrix portfolio.

VBL Therapeutics announced financial results for the second quarter ended June 30, 2021, and provided a corporate update.

JenaValve Technology, Inc. today announced FDA approval for the company to initiate its Investigational Device Exemption (IDE) PMA clinical trial for the Trilogy™ Heart Valve System for severe symptomatic, high-surgical risk aortic regurgitation.

atai Life Sciences N.V. today reported its financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Centene Corporation (NYSE: CNC) announced today Rich Fisher has been appointed to Senior Vice President and Medicare CEO.

Initiated Phase 2 open-label clinical study (APEX) for bezuclastinib (CGT9486) in patients with Advanced Systemic Mastocytosis (AdvSM)

Enanta Pharmaceuticals, Inc., today announced that it has dosed the first subject in its Phase 1 clinical trial of EDP-721, a novel, oral hepatitis B virus (HBV) RNA destabilizer being developed for use in an all-oral combination regimen for chronic HBV patients.

Rocket Pharmaceuticals, Inc. today announces that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company’s Phase 1 clinical trial of RP-A501 for the treatment of Danon Disease, allowing patient enrollment to resume.